Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New Drug application to the U.S. FDA for the mid-stage trial of intranasal foralumab to treat amyotrophic lateral sclerosis (ALS).

ALS is a